Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 2.0% in the 4th quarter, Holdings Channel reports. The fund owned 492,630 shares of the company’s stock after purchasing an additional 9,654 shares during the period. Geode Capital Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $9,744,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth $4,997,000. SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter worth about $355,000. Charles Schwab Investment Management Inc. boosted its stake in Kiniksa Pharmaceuticals by 36.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock worth $2,414,000 after buying an additional 32,393 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals in the 4th quarter valued at about $3,955,000. Finally, Globeflex Capital L P increased its stake in shares of Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock valued at $1,752,000 after acquiring an additional 60,656 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the sale, the insider now owns 9,415 shares in the company, valued at $191,030.35. This trade represents a 65.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 110,025 shares of company stock valued at $2,372,610. Company insiders own 54.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $20.88 on Thursday. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $28.15. The stock has a 50-day simple moving average of $21.10 and a 200-day simple moving average of $21.41. The stock has a market capitalization of $1.52 billion, a P/E ratio of -149.13 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter in the prior year, the firm earned $0.35 earnings per share. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% compared to the same quarter last year. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.